William Blair Has Positive Outlook of Medtronic Q3 Earnings

Medtronic PLC (NYSE:MDT) – Equities researchers at William Blair increased their Q3 2026 earnings per share (EPS) estimates for Medtronic in a research note issued to investors on Wednesday, November 19th. William Blair analyst B. Vazquez now forecasts that the medical technology company will earn $1.36 per share for the quarter, up from their previous forecast of $1.34. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the business earned $1.26 EPS. The company’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS.

Several other research analysts have also weighed in on the company. Leerink Partners set a $120.00 price objective on Medtronic and gave the stock an “outperform” rating in a research report on Wednesday. Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. JPMorgan Chase & Co. boosted their price target on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Morgan Stanley increased their price target on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Royal Bank Of Canada raised their price objective on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.72.

Medtronic Price Performance

MDT stock opened at $101.16 on Friday. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The firm has a market cap of $129.76 billion, a price-to-earnings ratio of 27.87, a PEG ratio of 2.42 and a beta of 0.77. The company’s fifty day simple moving average is $95.04 and its 200 day simple moving average is $90.94. Medtronic has a 12-month low of $79.29 and a 12-month high of $102.59.

Insider Activity at Medtronic

In related news, Director William R. Jellison acquired 2,500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were acquired at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.26% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDT. Brighton Jones LLC grew its holdings in Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares during the period. PFG Advisors grew its holdings in Medtronic by 55.0% during the 1st quarter. PFG Advisors now owns 4,144 shares of the medical technology company’s stock valued at $372,000 after buying an additional 1,471 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in Medtronic by 9.5% during the 1st quarter. Venturi Wealth Management LLC now owns 6,982 shares of the medical technology company’s stock valued at $627,000 after buying an additional 608 shares in the last quarter. J. W. Coons Advisors LLC bought a new stake in shares of Medtronic during the first quarter valued at about $216,000. Finally, AE Wealth Management LLC lifted its holdings in shares of Medtronic by 7.2% in the first quarter. AE Wealth Management LLC now owns 8,899 shares of the medical technology company’s stock worth $800,000 after buying an additional 597 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.